Integer Holdings (ITGR)
(Delayed Data from NYSE)
$126.17 USD
+1.92 (1.55%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $126.25 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$126.17 USD
+1.92 (1.55%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $126.25 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Integer Holdings (ITGR) Q1 Earnings Miss, View Impressive
by Zacks Equity Research
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises hopes.
Here's Why You Should Invest in Integer Holdings Right Now
by Zacks Equity Research
Integer Holdings' (ITGR) unswerving focus on customer relationship, cost reduction and burgeoning financial performance are key catalysts.
Here's Why You Should Invest in Stryker (SYK) Right Now
by Zacks Equity Research
Stryker (SYK) gains from stellar performance of the flagship Mako platform; guidance solid.
Should Value Investors Pick Integer Holdings (ITGR) Stock?
by Zacks Equity Research
Is Integer Holdings (ITGR) a great pick from the value investor's perspective right now? Read on to know more.
Integer Holdings (ITGR) Beats on Q4 Earnings, Issues '18 View
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter 2017 results benefit from strong performance in its Medical and Non-Medical units.
Cardiovascular Systems' Micro Crown Now Available in Japan
by Zacks Equity Research
Cardiovascular Systems (CSII) is positioned to gain from favorable trend in the CAD market.
Abiomed Hits New 52-Week High: 3 Factors Driving the Stock
by Zacks Equity Research
Abiomed (ABMD) recently reported strong preliminary third-quarter fiscal 2018 results.
Becton, Dickinson Completes Enrollment in Lutonix DCB Trial
by Zacks Equity Research
Becton, Dickinson's (BDX) focus in the Balloon-Angioplasty space is expected to lend the company a competitive edge in the niche MedTech markets.
Becton, Dickinson Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) rides on favorable regulatory developments and strategic acquisitions.
5 Reasons Why McKesson Deserves a Place in Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to pursue deals, divestitures and acquisitions to drive growth. The company's impressive performance in 2017 accounts for its potential to sustain the momentum.
Baxter (BAX) Launches Arisure Closed System Transfer Device
by Zacks Equity Research
Baxter's (BAX) Arisure Closed System reduces exposure risk of healthcare professionals to needles. Also, the latest development promotes safe handling of hazardous drugs.
Integra LifeSciences Estimates Strong Revenue Figures for Q4
by Zacks Equity Research
Integra LifeSciences (IART) sees strong organic growth in the company's Specialty Surgical Solutions as well as Orthopedics and Tissue Technologies businesses.
Surmodics (SRDX) Poised on Core Business Amid Forex Woes
by Zacks Equity Research
Surmodics' (SRDX) top line benefits from strong sales in Medical Device and IVD businesses. However, foreign currency is a headwind.
Abaxis' (ABAX) Preliminary Results for Q3 Cheer Investors
by Zacks Equity Research
Abaxis (ABAX) expects substantial tax savings from the recent U.S. tax reform.
Hill-Rom (HRC) Estimates Strong Revenue Figures for Q1
by Zacks Equity Research
Hill-Rom (HRC) expects substantial tax savings from the recent U.S. tax reform.
NuVasive Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
NuVasive (NUVA) continues to witness sequential growth in international revenues and expects substantial tax savings from the recent U.S. tax reform.
DexCom Estimates Strong Revenue Figures for Q4 and 2017
by Zacks Equity Research
Dexcom (DXCM) to gain from strong sensor volumes, international revenues and expanding worldwide patient base in 2018.
AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2
by Zacks Equity Research
Dwindling revenues in two major segments hurt AngioDynamics' (ANGO) second-quarter results.
McKesson Buys RxCrossroads from CVS Health for $735 Million
by Zacks Equity Research
McKesson (MCK) has been actively pursuing deals, divestitures and acquisitions to drive growth. The latest buyout will boost Specialty Health business.
Walgreens Boots (WBA) Tops Q1 Earnings, Margins Decline
by Zacks Equity Research
Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q1 on continued prescription growth and strength in the Retail Pharmacy USA division.
Neogen (NEOG) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Neogen (NEOG) rides high on balanced growth across all business segments in Q2.
Entellus (ENTL) Nears 52-Week High: What's Driving It?
by Zacks Equity Research
Entellus Medical Inc. (ENTL) gains from latest technology and promising revenue trends.
LabCorp Grapples With Reimbursement Cuts, Stiff Competition
by Zacks Equity Research
LabCorp (LH) faces intense competition from hospital-affiliated labs, primarily on the basis of quality of service.
Stryker's Global Foothold Strong Amid Product Recall Issue
by Zacks Equity Research
Stryker (SYK) enjoys strong foothold in the European and Australian markets. On the flip side, the company witnesses lower demand for health care products.
Anika Therapeutics Receives FDA Nod for Bone Repair Therapy
by Zacks Equity Research
Anika Therapeutics' (ANIK) FDA approved HA-based injectable bone repair therapy provides a commercial edge to regenerative portfolio.